Liver disease represents a cause for international concern. Chronic liver diseases currently account for ~4% of deaths worldwide, and rates continue to rise.1 Similarly, liver cancer, a terminal outcome of chronic liver disease, accounts for ~8% of global cancer deaths.2 These trends are closely linked to changes in obesity and alcohol-related harm particularly affecting low-income and middle-income countries.3 Within the UK, the burden of liver disease has reached its highest level on record, with hospital admissions and deaths rising sharply in the post-pandemic period.4 5 Although there is a pipeline of investigational therapies for cirrhosis,6–8 alongside curative treatments for certain liver diseases (eg, autoimmune and viral) and transplantation for a fortunate few, patient harms from liver cirrhosis are increasing year-on-year.
To deliver impact, clinical research requires the alignment of goals from patients and the public as well…
